

Docket No.: 207A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wang et al.

Serial No.: 10/840,138

Group: 1632


Filing Date: May 6, 2004

Examiner: to be assigned

Title: METHODS OF USING IL-1 ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA

Certificate of First Class Mailing

I hereby certify that this paper is being deposited on this date with the U. S. Postal Service as first class mail addressed to the Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.



Loren Hernandez



Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:


(b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Fees


No fee is required for the filing of this Information Disclosure Statement.

If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



FORM PTO-1449

Att. Docket No. 207A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant : Wang et al.
Serial No. : 10/840,138
Date Filed : May 6, 2004
For : METHODS OF USING IL-1
ANTAGONISTS TO TREAT
NEOINTIMAL HYPERPLASIA
Examiner : To be Assigned
Group Art Unit : 1632

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	<u>5,135,917</u>	<u>Aug. 4, 1992</u>	<u>Ronald M. Burch</u>		

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes</u>	<u>No</u>
_____	<u>WO 00/71753 A2</u>	<u>30 Nov 2000</u>	<u>PCT</u>			
_____	<u>WO 93/24134</u>	<u>9 Dec 1993</u>	<u>PCT</u>			
_____	<u>WO 00/18932</u>	<u>06 Apr. 2000</u>	<u>PCT</u>			

WO 02/16436 A2 28 Feb. 2002 PCT

WO 04/022718 A2 18 Mar. 2004 PCT

OTHER DOCUMENTS

**Examiner
Initials**


US Patent Application Publication No. US 2001/0053764 A1, Publication Date: December 20, 2001; "Interleukin-1 Inhibitors in the Treatment of Diseases".

US Patent Application Publication No. US 2003/0026806 A1, Publication Date: February 6, 2003; "Antibodies and Other Selective IL-1 Binding Agents that Allow Binding to IL-1 Receptor But Not Activation Thereof".

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,
By: 
Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400